Q2 2022 Scandion Oncology A/S Earnings Call Transcript
/-&
Thank you, and good morning, everyone. Welcome to our second-quarter 2022 interim report investor call. As you heard, my name is Bo Rode Hansen, and I'm the CEO and President of Scandion Oncology. And with me today is our Chief Financial Officer, Johnny Stilou. Johnny and I will be updating you on the developments and financial results for the second quarter of 2022, as well as recent events in the company.
We are very happy with our achievements in the quarter. First and foremost, raising capital to enhance our financial position. I'm also glad to report that we continue our strong operational execution and progress in our clinical trials. Following our presentation, Johnny and I are happy to take your questions.
Please be informed that in order to best address your questions, we ask you to state these verbally. It will not be possible to put questions forward in writing. So if you have a question, please follow the operator's instructions and ask verbally. Again, welcome, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |